ArticleGalen medical journal2024
Hypericin and Naringenin Exert no Significant Synergistic Apoptotic Effect on Y79 Retinoblastoma Cell Line.
Article in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccording to the anti-cancer impact of hypericin and naringenin, we put the main aim of this study to unravel the apoptotic/anti-cancer effect of these compounds on Y79 retinoblastoma cell line. MATERIALS AND
methodsTo calculate the 50%inhibitory concentration (IC50) of hypericin for 24 and 48 hours, XTT assay performed. Cytotoxic effect of naringenin investigated by XTT and trypan blue exclusion assay further confirmed the inhibitory impact of these agents on Y79 cells viability. Flow cytometry Annexin V/PI determined the cell death. The mRNAs expression level of Bax and Bcl-2 investigated by real-time PCR in different groups including the control, cells treated with naringenin, hypericin, or concurrent with both compounds.
resultsThe 24 and 48 hours IC50 of hypericin, calculated to be 2.5 and 1.25 (μg/ml), respectively. 50 (μg/ml) naringenin induced about 20% and 30% apoptosis in Y79 cells after 24 and 48 hours. Trypan blue staining and flow cytometry confirmed this data. Moreover, flowcytometry results, revealed that the kind cell death occurred in these cells post treatment was mostly apoptosis. Simultaneous treatment with both agents didn't show synergistic effect. Bax/Bcl-2 ratio increased in cells treated with hypericin but in cells treated with narigenin didn't show significant increase in the Bax mRNA level.
conclusionHypericin had more cytotoxic effect in Y79 cells compared with naringenin. Furthermore, hypericin and naringenin didn't have apoptotic synergistic effect in these cells. According to the real-time PCR results, hypericin induces apoptosis in Y79 cells by disrupt the ratio of Bax/Bcl-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.